These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 11996956)

  • 1. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
    Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L; Parris W; Adeli K; Cheung RC
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
    Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
    Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
    Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
    Ellen RL; McPherson R
    Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
    Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
    J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    Aberg JA; Zackin RA; Brobst SW; Evans SR; Alston BL; Henry WK; Glesby MJ; Torriani FJ; Yang Y; Owens SI; Fichtenbaum CJ;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):757-67. PubMed ID: 16218799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
    Hernández Mijares A
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate.
    Feher MD; Caslake M; Foxton J; Cox A; Packard CJ
    Diabetes Metab Res Rev; 1999; 15(6):395-9. PubMed ID: 10634964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.